Unlock stock picks and a broker-level newsfeed that powers Wall Street.
Actinium Pharmaceuticals Provides Business Update After Presentation at Trump Mar-A-Lago Club Announcing Novel Non-PSMA Prostate Cancer Radiotherapy ATNM-400 and Outlining Revitalized Clinical Pipeline with 2025 Corporate Objectives
- ATNM-400 is a novel, non-PSMA targeting, first-in-class Actinium-225 radiotherapy for prostate cancer with initial preclinical results to be presented at the AACR Annual Meeting
- Actinium is establishing radiopharmaceutical manufacturing infrastructure in 2025 to support expanding clinical trials and to leverage its proprietary Actinium-225 cyclotron manufacturing technology
- Data from several clinical trials expected in 2H:2025 across myeloid malignancies, solid tumors and cell and gene therapy conditioning
- Actinium's targeted radiotherapy programs expanded to four multi-billion-dollar market opportunities
NEW YORK, March 27, 2025 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today provided a business update detailing recent achievements and anticipated milestones from its revitalized and expanding clinical pipeline. The update featured the unveiling of ATNM-400, Actinium's new Actinium-225 (Ac-225) solid tumor program, which is a novel, non-PSMA targeting, first-in-class radiotherapy for prostate cancer. Initial preclinical data from ATNM-400 will be presented at AACR on April 27, 2025. In addition, Actinium highlighted its 2025 manufacturing infrastructure activity, including its Actinium-225 cyclotron manufacturing technology, to support its expanding clinical pipeline. Finally, Actinium highlighted several clinical trials that are expected to generate clinical data in the second half of 2025 including its Actimab-A frontline AML trial under its Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI), data from trials in the Actimab-A solid tumor program which combines Actimab-A with PD-1 checkpoint inhibitors KEYTRUDA® and OPDIVO® in head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC) and Iomab-ACT commercial CAR-T and sickle cell disease (SCD) trials.
(PRNewsfoto/Actinium Pharmaceuticals, Inc.)
This update follows Actinium's company presentation at Trump Mar-a-Lago Club on March 26th and an Actimab-A KOL investor call on March 25th, which can be accessed for replay here.
Sandesh Seth, Actinium's Chairman and CEO, said, "We are resurgent and expect 2025 will be an impactful year for Actinium as we execute to demonstrate the inherent value of our truly innovative and first of their kind clinical programs that focus on patients with high unmet needs. We are thrilled to introduce ATNM-400 and we look forward to presenting our promising preclinical results at AACR in April. We believe a significant opportunity exists in prostate cancer for ATNM-400, particularly for patients progressing or not well served by the PSMA targeting radiotherapy Pluvicto given its novel target and the potent cell killing ability of the Ac-225 isotope payload. In conjunction with advancing our clinical programs, several of which are expected to generate clinical data this year, we are building out manufacturing infrastructure in 2025 to support these programs which are expected to enter advanced development in 2026. Our strong balance sheet with cash runway expected to last into mid-2027 allows us to focus on unlocking the value inherent in our pipeline which has four distinct blockbuster opportunities with Actimab-A in hematology and solid tumors, Iomab-ACT in cell and gene therapy conditioning and now ATNM-400 in prostate cancer."
Actinium's 2025 achievements to date including the following:
Unveiled ATNM-400, a first-in-class, novel non-PSMA targeting Actinium-225 radiotherapy for prostate cancer with initial preclinical data to be presented at AACR on April 27, 2025
Initiated Actimab-A frontline AML triplet trial under NCI CRADA that will study Actimab-A as a backbone in combination with Venetoclax and ASTX-727, an oral hypomethylating agent developed by Taiho oncology, Inc., an Otsuka Holdings company
Results of Actimab-A + CLAG-M combination trial published in the peer-reviewed journal Leukemia highlighting high rates of MRD- and improved overall survival in patients with r/r AML
Initiated Actimab-A solid tumor program to combine Actimab-A with PD-1 checkpoint inhibitors KEYTRUDA and OPDIVO in head-to-head trials in head and neck squamous cell carcinoma and non-small cell lung cancer
Entered into sponsored research agreements with Memorial Sloan Kettering Cancer Center to further elucidate Actimab-A's mutation agnostic mechanism of action and potential as a backbone therapy in myeloid malignancies
Executed a supply agreement with Exckert & Ziegler for Actinium-225 Radioisotope to support comprehensive development activities for both U.S. and international clinical trials
Abstracts accepted for presentation at the American Association for Cancer Research Annual Meeting highlighting Actimab-A's mutation agnostic profile in AML
Actinium's pipeline revitalization has resulted in expanded market opportunities for its first-in-class targeted radiotherapies in myeloid malignancies, solid tumors and cell and gene therapy conditioning. Actinium seeks to address four distinct blockbuster opportunities with ATNM-400, Actimab-A and Iomab-ACT.
Actinium outlined its 2025 business objectives for its revitalized and expanding clinical pipeline as follows:
Pipeline Expansion into Prostate Cancer with ATNM-400, a first-in-class, non-PSMA targeting Ac-225 radiotherapy
Present abstract at AACR highlighting Actinium-225 targeted radiotherapy for novel radiotherapy cancer target
Establish In-house Radiopharmaceutical Manufacturing & Production
Actimab-A as a mutation agnostic, backbone therapy for myeloid malignancies including acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) across multiple treatment settings
Initiate Phase 2/3 trial in combination with CLAG-M in relapsed or refractory AML and seek potential partners or collaborators
Generate initial clinical data in frontline AML in first trial under CRADA with NCI
Initiate additional clinical trials in myeloid malignancies
Actimab-A as a pan solid tumor therapy in combination with PD-1 inhibitors including KEYTRUDA and OPDIVO by depleting myeloid derived suppressor cells (MDSCs)
Generate clinical proof of concept data in head and neck squamous cell carcinoma and non-small cell lung cancer
Explore additional solid tumor indications for future trials
Iomab-ACT as a universal targeted conditioning agent to increase patients access to cell & gene therapies and improve patient outcomes
Present initial data from commercial CAR-T trial at University of Texas Southwestern
Generate clinical data in first non-malignant indication from sickle cell disease allogeneic stem cell transplant trial at Columbia University
About Actinium Pharmaceuticals, Inc.
Actinium is a pioneer in the development of targeted radiotherapies intended to meaningfully improve patient outcomes. Actinium is advancing its lead product candidate Actimab-A, a CD33 targeting therapeutic, as potential backbone therapy in acute myeloid leukemia (AML) and other myeloid malignancies leveraging the mutation agnostic alpha-emitter radioisotope payload Actinium-225 (Ac-225). Actimab-A has demonstrated potential activity in relapsed and refractory acute myeloid leukemia (r/r AML) patients in combination with the chemotherapy CLAG-M including high rates of Complete Remissions (CR) and measurable residual disease (MRD) negativity leading to improved survival outcomes and is being advanced to a pivotal Phase 2/3 trial. In addition, Actinium is engaged with the National Cancer Institute (NCI) under the Cooperative Research and Development Agreement (CRADA) for development of Actimab-A in AML and other myeloid malignancies. The first clinical trial under the CRADA will evaluate the triplet combination comprised of Actimab-A, Venetoclax (Abbvie/Roche) an oral Bcl-2 inhibitor and ASTX-727 (Taiho Oncology, an Otsuka holdings company) a novel oral hypomethylating agent (HMA) in frontline acute myeloid leukemia (AML) patients. Additionally, Actinium is developing Actimab-A as a potential pan tumor therapy in combination with PD-1 checkpoint inhibitors including KEYTRUDA® and OPDIVO® by depleting myeloid derived suppressor cells (MDSCs), which represents a potential multi-billion-dollar addressable market. Iomab-ACT, Actinium's next generation conditioning candidate, is being developed with the goal of improving patient access and outcomes for potentially curative cell and gene therapies. Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with r/r AML, which Actinium is seeking a potential strategic partner for the U.S. ATNM-400 is Actinium's novel non-PSMA targeting Ac-225 radiotherapy for prostate cancer, which is supported by preclinical data and is being advanced to clinical trials. In addition, the company's R&D efforts are primarily focused on advancing several preclinical programs for solid tumor indications. Actinium holds 230 patents and patent applications including several patents related to the manufacture of the isotope Ac-225 in a cyclotron.
This press release may contain projections or other "forward-looking statements" within the meaning of the "safe-harbor" provisions of the private securities litigation reform act of 1995 regarding future events or the future financial performance of the Company which the Company undertakes no obligation to update. These statements are based on management's current expectations and are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with preliminary study results varying from final results, estimates of potential markets for drugs under development, clinical trials, actions by the FDA and other governmental agencies, regulatory clearances, responses to regulatory matters, the market demand for and acceptance of Actinium's products and services, performance of clinical research organizations and other risks detailed from time to time in Actinium's filings with the Securities and Exchange Commission (the "SEC"), including without limitation its most recent annual report on form 10-K, subsequent quarterly reports on Forms 10-Q and Forms 8-K, each as amended and supplemented from time to time.
